Lupin Laboratories of India is establishing joint ventures in China, Russia and South Africa, holding a majority stake in all three, reports the Marketletter's Indian correspondent.
In China and Russia, Lupin Laboratories plans to set up manufacturing units with local partners, while the tie-up will be for marketing in South Africa.
President of international business at Lupin, Lalit Kumar, was quoted in a report as saying that the company had applied for permission to the Chinese equivalent of the Foreign Investment Promotion Board to set up two joint ventures with different partners to manufacture injectables.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze